Esophageal Absorption in EoE
Overview
Tab Title Description
Study type
InterventionalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 13-009092
NCT ID: NCT02314455
Sponsor Protocol Number: 13-009092
About this study
To determine how the esophagus in active and inactive stages of eosinophilic esophagitis transmit fluids.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Patients between the ages of 18 and 80 with eosinophilic esophagitis diagnosed by a combination of compatible symptoms, endoscopic findings, histology, and lack of response to proton pump inhibitors or negative pH study
- endoscopy with esophageal and duodenal biopsies within two weeks of performance of this study
- Patients between the ages of 18 and 80 with eosinophilic esophagitis diagnosed by a combination of compatible symptoms, endoscopic findings, histology, and lack of response to proton pump inhibitors or negative pH study, and are now in histologic remission( <15phf) by the use of steroids or the six food elimination diet.
- Volunteers will be selected for not having any history of esophageal symptoms
Exclusion Criteria:
- Vulnerable populations, such as those with diminished mental acuity, will be excluded.
- Patients taking Nsaids within 48 hours of the d-xylose testing
- artificial sweeteners within 48 hours of the d-xylose testing
- History of IBD
- Currently smoking or history of smoking
- History of Celiac disease
- Bacterial overgrowth,
- motility disorders
- other diffuse small bowel diseases.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator David Katzka, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available